Cargando…

A New Approach to Assess Blinding for Transcranial Direct Current Stimulation Treatment in Patients with Fibromyalgia. A Randomized Clinical Trial

Correct blinding is essential for preventing potential biases. The aim of this study was to assess the blinding of participants and a therapist following treatment with transcranial direct current stimulation in subjects with fibromyalgia using James’ and Bang’s blinding indexes. Eighty subjects wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Arroyo-Fernández, Rubén, Avendaño-Coy, Juan, Velasco-Velasco, Rafael, Palomo-Carrión, Rocío, Bravo-Esteban, Elisabeth, Ferri-Morales, Asunción
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533681/
https://www.ncbi.nlm.nih.gov/pubmed/34679399
http://dx.doi.org/10.3390/brainsci11101335
_version_ 1784587371880120320
author Arroyo-Fernández, Rubén
Avendaño-Coy, Juan
Velasco-Velasco, Rafael
Palomo-Carrión, Rocío
Bravo-Esteban, Elisabeth
Ferri-Morales, Asunción
author_facet Arroyo-Fernández, Rubén
Avendaño-Coy, Juan
Velasco-Velasco, Rafael
Palomo-Carrión, Rocío
Bravo-Esteban, Elisabeth
Ferri-Morales, Asunción
author_sort Arroyo-Fernández, Rubén
collection PubMed
description Correct blinding is essential for preventing potential biases. The aim of this study was to assess the blinding of participants and a therapist following treatment with transcranial direct current stimulation in subjects with fibromyalgia using James’ and Bang’s blinding indexes. Eighty subjects were randomly allocated either active or sham stimulation groups in an intervention of five sessions lasting 20 min each. A questionnaire was delivered to both the therapist and patients after the last session to record their guess of which treatment had been applied. No differences between the groups were noted at baseline in terms of demographic or clinical data. James’ BI was 0.83 (CI 95%: 0.76–0.90) for the patients and 0.55 (CI 95%: 0.45–0.64) for the therapist. Bang’s BI for subjects was −0.08 (CI 95%: −0.24–0.09) and −0.8 (CI 95%: −0.26–0.1) for the active and sham transcranial direct current stimulation groups, respectively. Bang’s BI for the therapist was 0.21 (CI 95%: −0.02–0.43) and 0.13 (CI 95%: −0.09–0.35) for the active and sham transcranial direct current stimulation groups, respectively. Protocols of active and sham transcranial direct current stimulation applied in this study have shown satisfactory blinding of the therapist and subjects with fibromyalgia.
format Online
Article
Text
id pubmed-8533681
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85336812021-10-23 A New Approach to Assess Blinding for Transcranial Direct Current Stimulation Treatment in Patients with Fibromyalgia. A Randomized Clinical Trial Arroyo-Fernández, Rubén Avendaño-Coy, Juan Velasco-Velasco, Rafael Palomo-Carrión, Rocío Bravo-Esteban, Elisabeth Ferri-Morales, Asunción Brain Sci Article Correct blinding is essential for preventing potential biases. The aim of this study was to assess the blinding of participants and a therapist following treatment with transcranial direct current stimulation in subjects with fibromyalgia using James’ and Bang’s blinding indexes. Eighty subjects were randomly allocated either active or sham stimulation groups in an intervention of five sessions lasting 20 min each. A questionnaire was delivered to both the therapist and patients after the last session to record their guess of which treatment had been applied. No differences between the groups were noted at baseline in terms of demographic or clinical data. James’ BI was 0.83 (CI 95%: 0.76–0.90) for the patients and 0.55 (CI 95%: 0.45–0.64) for the therapist. Bang’s BI for subjects was −0.08 (CI 95%: −0.24–0.09) and −0.8 (CI 95%: −0.26–0.1) for the active and sham transcranial direct current stimulation groups, respectively. Bang’s BI for the therapist was 0.21 (CI 95%: −0.02–0.43) and 0.13 (CI 95%: −0.09–0.35) for the active and sham transcranial direct current stimulation groups, respectively. Protocols of active and sham transcranial direct current stimulation applied in this study have shown satisfactory blinding of the therapist and subjects with fibromyalgia. MDPI 2021-10-11 /pmc/articles/PMC8533681/ /pubmed/34679399 http://dx.doi.org/10.3390/brainsci11101335 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arroyo-Fernández, Rubén
Avendaño-Coy, Juan
Velasco-Velasco, Rafael
Palomo-Carrión, Rocío
Bravo-Esteban, Elisabeth
Ferri-Morales, Asunción
A New Approach to Assess Blinding for Transcranial Direct Current Stimulation Treatment in Patients with Fibromyalgia. A Randomized Clinical Trial
title A New Approach to Assess Blinding for Transcranial Direct Current Stimulation Treatment in Patients with Fibromyalgia. A Randomized Clinical Trial
title_full A New Approach to Assess Blinding for Transcranial Direct Current Stimulation Treatment in Patients with Fibromyalgia. A Randomized Clinical Trial
title_fullStr A New Approach to Assess Blinding for Transcranial Direct Current Stimulation Treatment in Patients with Fibromyalgia. A Randomized Clinical Trial
title_full_unstemmed A New Approach to Assess Blinding for Transcranial Direct Current Stimulation Treatment in Patients with Fibromyalgia. A Randomized Clinical Trial
title_short A New Approach to Assess Blinding for Transcranial Direct Current Stimulation Treatment in Patients with Fibromyalgia. A Randomized Clinical Trial
title_sort new approach to assess blinding for transcranial direct current stimulation treatment in patients with fibromyalgia. a randomized clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533681/
https://www.ncbi.nlm.nih.gov/pubmed/34679399
http://dx.doi.org/10.3390/brainsci11101335
work_keys_str_mv AT arroyofernandezruben anewapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT avendanocoyjuan anewapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT velascovelascorafael anewapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT palomocarrionrocio anewapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT bravoestebanelisabeth anewapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT ferrimoralesasuncion anewapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT arroyofernandezruben newapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT avendanocoyjuan newapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT velascovelascorafael newapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT palomocarrionrocio newapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT bravoestebanelisabeth newapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial
AT ferrimoralesasuncion newapproachtoassessblindingfortranscranialdirectcurrentstimulationtreatmentinpatientswithfibromyalgiaarandomizedclinicaltrial